The Danish Ministry of Economy stated that the country’s GDP (Gross Domestic Product) will grow at a faster pace than previously predicted. The reason for the acceleration is the sales boom in the pharmaceutical industry, dominated by Novo Nordisk.
The estimate is for growth of 2.7% in 2026. Pharmaceutical companies should be responsible for one percentage point in the indicator. The previous forecast, released in December, was growth of 2.2%.
The new forecast is further evidence of the resilience of the Danish economy, despite the recent discouraging news surrounding Novo Nordisk, which has struggled to maintain the growth momentum of its weight-loss drug, Wegovy, amid increased competition.
Earlier this week, first-quarter GDP data released by the Danish National Statistics Institute showed better-than-expected growth of 1.9% compared to the previous quarter, driven mainly by the pharmaceutical sector.
The Ministry’s new estimate comes at a time when Denmark does not have a permanent government following March’s national elections. King Frederick X is expected to formally appoint interim Prime Minister Mette Frederiksen to begin the third round of negotiations to form the government.
